Skip to main content

Articles

Page 12 of 12

  1. Intermediate uveitis (IU) is generally believed to be autoimmune in nature requiring systemic corticosteroid and immunomodulatory therapy. This belief stems from the published reports from the developed countr...

    Authors: Swapnil Parchand, Manjari Tandan, Vishali Gupta and Amod Gupta
    Citation: Journal of Ophthalmic Inflammation and Infection 2011 1:20
  2. Secondary glaucoma is a difficult and frequent complication of uveitis. The aim of this study is to describe the results of surgery in uveitic glaucoma and to identify situations linked to a high risk of failu...

    Authors: Ester Carreño, Sonia Villarón, Alejandro Portero, José M. Herreras, José A. Maquet and Margarita Calonge
    Citation: Journal of Ophthalmic Inflammation and Infection 2010 1:12
  3. Chemotherapy with bevacizumab alters the angiogenic environment, and therefore, the growth and spread of metastases. We present a patient with metastatic lung adenocarcinoma to the eye with findings suggestive...

    Authors: Efrem D. Mandelcorn, Alan G. Palestine, Sandor Dubovy and Janet L. Davis
    Citation: Journal of Ophthalmic Inflammation and Infection 2010 1:13
  4. The aim of this report is to present a previously unreported causative organism associated with brown-pigmented hypopyon in a patient with endophthalmitis.

    Authors: Adam Hauch, Dean Eliott, Narsing A. Rao, Daniel V. Vasconcelos-Santos, Thomas O’Hearn and Amani A. Fawzi
    Citation: Journal of Ophthalmic Inflammation and Infection 2010 1:8
  5. Uveitis comprises an extensive array of intraocular inflammatory diseases and often results in irreversible visual loss. Experimental autoimmune uveitis (EAU) is an animal model used to study human uveitis. Bo...

    Authors: Angeline M. Nguyen and Narsing A. Rao
    Citation: Journal of Ophthalmic Inflammation and Infection 2010 1:7

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 2.9
    5-year Journal Impact Factor: 2.7
    Source Normalized Impact per Paper (SNIP): 1.135
    SCImago Journal Rank (SJR): 0.749

    Speed 2023
    Submission to first editorial decision (median days): 7
    Submission to acceptance (median days): 116

    Usage 2023
    Downloads: 409,704
    Altmetric mentions: 274